Unresectable Gallbladder Cancer Completed Phase 2 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0028792 (Unresectable Gallbladder Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00101036Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryTreatment
NCT00107536Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerTreatment